doi:10.48130/git-0025-0010

[1]

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, et al. 2017. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology 3:1335−42

doi: 10.1001/jamaoncol.2017.0589

[2]

Sei Y, Feng J, Zhao X, Wank SA. 2020. Role of an active reserve stem cell subset of enteroendocrine cells in intestinal stem cell dynamics and the genesis of small intestinal neuroendocrine tumors. American Journal of Physiology Gastrointestinal and Liver Physiology 319:G494−G501

doi: 10.1152/ajpgi.00278.2020

[3]

Imam R, Imam A, Atlan K, Mintz Y, Khoury T, et al. 2020. Gastric goblet cell carcinoma concurrent with a neuroendocrine tumor. Pathology - Research and Practice 216:153092

doi: 10.1016/j.prp.2020.153092

[4]

Sundqvist BZ, Kilpinen SK, Böhling TO, Koljonen VSK, Sihto HJ. 2023. Transcriptomic analyses reveal three distinct molecular subgroups of Merkel cell carcinoma with differing prognoses. International Journal of Cancer 152:2099−108

doi: 10.1002/ijc.34425

[5]

Xu Z, Wang L, Dai S, Chen M, Li F, et al. 2021. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Network Open 4:e2124750

doi: 10.1001/jamanetworkopen.2021.24750

[6]

Fitzgerald TL, Mosquera C, Lea CS, McMullen M. 2017. Primary site predicts grade for gastroenteropancreatic neuroendocrine tumors. American Surgeon 83:799−803

doi: 10.1177/000313481708300741

[7]

Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, et al. 2016. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172−85

doi: 10.1159/000443167

[8]

Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, et al. 2022. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Review of Endocrinology & Metabolism 17:389−403

doi: 10.1080/17446651.2022.2099840

[9]

Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, et al. 2019. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 165:644−51

doi: 10.1016/j.surg.2018.09.006

[10]

Zheng M, Li Y, Li T, Zhang L, Zhou L. 2019. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. Cancer Medicine 8:5128−36

doi: 10.1002/cam4.2431

[11]

Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, et al. 2019. Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas. Neuroendocrinology 109:100−12

doi: 10.1159/000497336

[12]

Yang Z, Liang J, Leng K, Shi G. 2022. Survival benefit of surgical resection for pancreatic neuroendocrine tumors with oligometastatic liver metastasis: a retrospective and propensity score-matching analysis. Frontiers in Oncology 12:903560

doi: 10.3389/fonc.2022.903560

[13]

Edge SB, Compton CC. 2010. The American Joint Committee on Cancer: the 7^th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 17:1471−74

doi: 10.1245/s10434-010-0985-4

[14]

Öberg K, Åkerström G, Rindi G, Jelic S. 2010. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:v223−v227

doi: 10.1093/annonc/mdq192

[15]

Pu N, Habib JR, Bejjani M, Yin H, Nagai M, et al. 2021. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Annals of Translational Medicine 9:329

doi: 10.21037/atm-20-5348

[16]

Chen J, Liu Y, Xu K, Ren F, Li B, et al. 2022. Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas. Frontiers in Oncology 12:999012

doi: 10.3389/fonc.2022.999012

[17]

Poleé IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, et al. 2022. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study. European Journal of Cancer 172:252−63

doi: 10.1016/j.ejca.2022.06.003

[18]

Huang PY, Tsai KL, Liang CM, Tai WC, Rau KM, et al. 2018. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. The Kaohsiung Journal of Medical Sciences 34:650−56

doi: 10.1016/j.kjms.2018.05.009

[19]

Mafficini A, Scarpa A. 2019. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocrine Reviews 40:506−36

doi: 10.1210/er.2018-00160

[20]

Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, et al. 2024. Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms. Expert Review of Endocrinology & Metabolism 19:49−61

doi: 10.1080/17446651.2023.2279540

[21]

Fang C, Wang W, Feng X, Sun J, Zhang Y, et al. 2017. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer 117:1544−50

doi: 10.1038/bjc.2017.315

[22]

Zhou XP, Sun LB, Liu WH, Song XY, Gao Y, et al. 2025. Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 15:9510

doi: 10.1038/s41598-025-92974-x

[23]

Panzuto F, Massironi S, Partelli S, Campana D, Rinzivillo M, et al. 2020. Gastro-entero-pancreatic neuroendocrine neoplasia: the rules for non-operative management. Surgical Oncology 35:141−48

doi: 10.1016/j.suronc.2020.08.015

[24]

Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, et al. 2020. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 31:844−60

doi: 10.1016/j.annonc.2020.03.304

[25]

Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, et al. 2019. Is resection of primary midgut neuroendocrine tumors in patients with unresectable metastatic liver disease justified? A systematic review and meta-analysis. Journal of Gastrointestinal Surgery 23:1044−54

doi: 10.1007/s11605-018-04094-9

[26]

Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, et al. 2019. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Annals of Surgery 270:1131−37

doi: 10.1097/SLA.0000000000002809

[27]

Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, et al. 2015. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbeck's Archives of Surgery 400:715−23

doi: 10.1007/s00423-015-1323-x

[28]

Cives M, Strosberg JR. 2018. Gastroenteropancreatic neuroendocrine tumors. CA: A Cancer Journal for Clinicians 68:471−87

doi: 10.3322/caac.21493

[29]

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, et al. 2017. Long-term efficacy, survival, and safety of [¹⁷⁷Lu-DOTA⁰, Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clinical Cancer Research 23:4617−24

doi: 10.1158/1078-0432.CCR-16-2743

[30]

Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. 2020. Somatostatin analogs in clinical practice: a review. International Journal of Molecular Sciences 21:1682

doi: 10.3390/ijms21051682

[31]

Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, et al. 2021. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 70:1768−81

doi: 10.1136/gutjnl-2020-321300

[32]

Kawasaki K, Fujii M, Sato T. 2018. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Disease Models & Mechanisms 11:dmm.029595

doi: 10.1242/dmm.029595

[33]

Huang YC, Yang NN, Chen HC, Huang YL, Yan WT, et al. 2021. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients. World Journal of Gastroenterology 27:624−40

doi: 10.3748/wjg.v27.i7.624

[34]

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, et al. 2014. Recommendations for management of patients with neuroendocrine liver metastases. The Lancet Oncology 15:e8−21

doi: 10.1016/S1470-2045(13)70362-0

[35]

Mamoon N, Naveed H, Abid M, Nasir H, Ahmad IN, et al. 2021. Gastroenteropancreatic neuroendocrine tumours: Clinicopathological evaluation at Shifa International Hospital, Islamabad. The Journal of the Pakistan Medical Association 71:492−96

doi: 10.47391/JPMA.835

[36]

Zamborsky R, Svec A, Kokavec M, Galbavy S. 2017. Bone metastases in neuroendocrine tumors. Bratislavske Lekarske Listy 118:529−34

doi: 10.4149/BLL_2017_102

[37]

Zheng Z, Chen C, Jiang L, Zhou X, Dai X, et al. 2019. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: a population-based study. Cancer Medicine 8:7288−98

doi: 10.1002/cam4.2567

[38]

Tarquini M, Ambrosio MR, Albertelli M, de Souza PB, Gafa R, et al. 2021. A tool to predict survival in stage IV entero-pancreatic NEN. Journal of Endocrinological Investigation 44:1185−92

doi: 10.1007/s40618-020-01404-4

[39]

Pusceddu S, Barretta F, Trama A, Botta L, Milione M, et al. 2018. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer 25:607−18

doi: 10.1530/ERC-17-0489